SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced that it is filing today an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial with its next-generation drug candidate HE3286 for the treatment of metabolic disorders, which include diabetes, obesity and dyslipidemia. The Phase I trial program, designed to assess the safety of HE3286 in healthy volunteers, could support both a Phase II study in type 2 diabetes patients, as well as a Phase II study in rheumatoid arthritis patients under a separate IND the Company plans to file for autoimmune disorders later this year. In preclinical studies, HE3286 has been shown to regulate signaling pathways of inflammation common to both metabolic and autoimmune disorders.
